Pricing Log in Create free account

Incyte Corporation (INCY) vs Royalty Pharma PLC (RPRX)

Incyte Corporation and Royalty Pharma PLC are both Biotechnology companies. Royalty Pharma PLC is the larger, with a market value of $39.0B against $24.1B — 1.6× the size. Royalty Pharma PLC trades at the lower P/E: 44.8× against 56.3×. Incyte Corporation grew revenue faster over the last twelve months: 24.9% against 11.4%. Incyte Corporation has the higher net margin (6.71% vs 0.00%) and the higher return on invested capital (21.6% vs 5.24%). Across the 22 metrics below, Incyte Corporation leads on 13 and Royalty Pharma PLC on 9.

Valuation

Metric INCY RPRX Biotechnology median
P/E 56.33 44.80 10.26
P/S 4.00 11.53 9.18
P/B 4.26 3.08 2.05
Price to free cash flow 35.34 23.33 24.81
EV/EBITDA 27.88 24.70 0.65
EV/Sales 3.36 14.60 8.98
Earnings yield 1.78% 2.23% (34.89%)
Free cash flow yield 2.83% 4.29% (24.52%)

Profitability

Metric INCY RPRX Biotechnology median
Gross margin 92.69% 100.00% 65.16%
Operating margin 10.42% 57.14% 0.00%
Net margin 6.71% 0.00% 0.00%
Free cash flow margin 11.31% 113.11% 0.00%
Return on equity 7.84% 0.00% (50.12%)
Return on assets 5.92% 0.00% (45.60%)
Return on invested capital 21.56% 5.24% 0.00%

Growth

Metric INCY RPRX Biotechnology median
Revenue growth (TTM) 24.88% 11.36% 6.26%
EPS growth (last fiscal year) 4,173.33% (6.81%) 29.88%
Revenue growth, 5-year CAGR 14.03% 2.30% 9.75%
Net income growth, 5-year CAGR 0.00% (4.59%) 0.00%

Health

Metric INCY RPRX Biotechnology median
Debt to equity 0.00 0.88 0.00
Current ratio 3.84 1.29 4.89
Net debt to EBITDA (2.21) 5.22 1.01

Dividend

Metric INCY RPRX Biotechnology median
Dividend yield — 1.37% 0.41%
Payout ratio — 0.66 —

Size

Metric INCY RPRX Biotechnology median
Market cap 24.05b 38.95b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack